Takeda is seeking FDA approval for its drug ORZEYFUL.
10 reports, 4 independent
Updated Thu 00:00
Mostly repetition
- Reports
- 10
- Developments
- 3
- Repetition
- 70%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Takeda is seeking FDA approval for its drug ORZEYFUL.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.ORZEYFUL receives approvals in Japan and China; US launch pending DEA scheduling.1 source
FDA approved ORZEYFUL for treatment, and the drug is now available in the US, Japan, and China.1 source
Takeda seeks FDA approval for ORZEYFUL.1 source
Keep exploring
The entities involved
Related events
- FDA approval supports NDA submission in Aurora.
- The FDA requested additional clinical data from Unicycive Therapeutics.
- Clene Inc. submitted an NDA to the FDA seeking accelerated approval while trading on the Nasdaq exchange.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- Argenx SE announced it is listed on Nasdaq and is seeking FDA priority review and approval.